Day One Biopharmaceuticals shares jumped 26.7% in the most recent session on trading volume of 1.2 million shares, 50% above the 30-day average of 800,000 shares. This spike followed an announcement of preliminary data from an ongoing Phase II trial showing a 60% response rate in adult patients with rare genetic disorders. Despite the rally, the trend in consensus earnings estimate revisions has weakened: over the past month, five analysts have lowered their fiscal 2024 loss-per-share forecasts from -$3.10 to -$3.25, while only two have issued upgrades. Investor focus remains squarely on whether the stock can sustain momentum given the dampening revisions.

At the 44th Annual J.P. Morgan Healthcare Conference, CEO Jeremy Bender and his leadership team outlined strategic milestones. They reported that since the product’s Q2 2023 launch, OJEMDA has treated more than 1,000 children, driving $45 million in global revenue during Q4. The company now has three additional molecules in early clinical development targeting rare pediatric indications, with the next readout for its Phase Ib program expected in mid-year. Management reiterated guidance for investing $90 million in R&D this year to expand their pipeline and pursue two new IND filings by Q3.